SVILE 方案，即地塞米松、长春碱、异环磷酰胺、培门冬酶和依托泊苷联合方案，用于治疗复发/难治性结外鼻型自然杀伤/T 细胞淋巴瘤。
SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
机构信息
Department of Hematology, Beijing Tongren Hospital, Capital Medical University, No. 1 Dong Jiao Min Xiang Street, Dong Cheng District, Beijing, 100730, China.
Department of Hematology, Beijing Tongren Hospital, Capital Medical University, No. 1 Dong Jiao Min Xiang Street, Dong Cheng District, Beijing, 100730, China; Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beihang University & Capital Medical University, Beijing Tongren Hospital, Beijing, 100730, China.
出版信息
Leuk Res. 2020 Sep;96:106422. doi: 10.1016/j.leukres.2020.106422. Epub 2020 Jul 16.
OBJECTIVE
To explore the effectiveness and safety of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide combination (SVILE regimen) in the treatment of relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type (R/R-ENKTL).
METHODS
This descriptive, retrospective medical chart review assessed data from 20 R/R-ENKTL patients treated with the SVILE regimen between November 2014 and August 2019. Complete response (CR) rate, overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) since SVILE treatment were analysed.
RESULTS
After receiving 1-5 SVILE regimen chemotherapy cycles (median 2 cycles), patients had ORR and CR rates of 70.0 % and 45.0 %, respectively. Stage Ⅰ/Ⅱ patients had CR rate of 100.0 % and stage Ⅲ/Ⅳ patients had ORR and CR rates of 60.0 % and 26.7 %, respectively. Three-year PFS and OS rates of the 20 patients were 43.8 % and 54.2 %, respectively. Three-year PFS and OS rates of stage Ⅰ/Ⅱ patients and stage Ⅲ/Ⅳ patients were 100.0 % vs. 26.7 % and 100.0 % vs. 40.0 % (P ＜ 0.05), respectively. The PFS and OS of patients who achieved CR after SVILE chemotherapy were significantly better than those of non-CR patients. The main adverse events were reversible haematological toxicity.
CONCLUSIONS
The SVILE regimen is a new treatment option that is effective and safe for R/R-ENKTL patients.
目的
探索地塞米松、长春碱、异环磷酰胺、培门冬酶和依托泊苷联合（SVILE 方案）治疗复发/难治性结外鼻型自然杀伤/T 细胞淋巴瘤（R/R-ENKTL）的有效性和安全性。
方法
本描述性、回顾性病历研究评估了 2014 年 11 月至 2019 年 8 月期间接受 SVILE 方案治疗的 20 例 R/R-ENKTL 患者的数据。分析了 SVILE 治疗后完全缓解（CR）率、总缓解率（ORR）、无进展生存期（PFS）和总生存期（OS）。
结果
患者接受 1-5 个 SVILE 方案化疗周期（中位数 2 个周期）后，ORR 和 CR 率分别为 70.0%和 45.0%。Ⅰ/Ⅱ期患者 CR 率为 100.0%，Ⅲ/Ⅳ期患者 ORR 和 CR 率分别为 60.0%和 26.7%。20 例患者的 3 年 PFS 和 OS 率分别为 43.8%和 54.2%。Ⅰ/Ⅱ期和Ⅲ/Ⅳ期患者的 3 年 PFS 和 OS 率分别为 100.0%比 26.7%和 100.0%比 40.0%（P＜0.05）。SVILE 化疗后达到 CR 的患者的 PFS 和 OS 明显优于未达到 CR 的患者。主要不良事件为可逆性血液学毒性。
结论
SVILE 方案是一种治疗 R/R-ENKTL 患者的有效且安全的新治疗选择。
Zotero 插件